Non-Therapeutic Biomolecules Global Market Report 2024

The primary classifications of non-therapeutic biomolecules in traditional pharmaceuticals encompass enzymes, recombinant proteins, plasmids, peptides, oligonucleotides, and monoclonal antibodies. Enzymes, for instance, are specialized globular proteins that accelerate biological reactions by lowering the activation energy needed for these processes. These biomolecules find application across diverse sectors including research, pharmaceuticals, and in vitro diagnostics (IVD), contributing significantly to various end-users' operational needs.

This report provides non-therapeutic biomolecules market statistics, including the non-therapeutic biomolecules industry’s global market size, regional shares, competitors with a non-therapeutic biomolecules market share, detailed non-therapeutic biomolecules market segments, market trends, and opportunities, and any further data you may need to thrive in the non-therapeutic biomolecules industry. This non-therapeutic biomolecules market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global non-therapeutic biomolecules market has grown rapidly in recent years. It will grow from $27.91 billion in 2023 to $31.11 billion in 2024 at a compound annual growth rate (CAGR) of 11.4%. The growth observed in the historical period can be attributed to several factors, including amplified investments in research and development (R&D), expanding applications in research and diagnostics, an increase in awareness and subsequent adoption, strategic collaborations and partnerships within the industry, and regulatory support fostering advancement in the field.

The global non-therapeutic biomolecules market is expected to see rapid growth in the next few years. It will grow to $47.21 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The anticipated growth in the upcoming period can be credited to emerging market opportunities, advancements in data analytics and integration, a heightened emphasis on precision medicine, escalating investments in personalized healthcare, and the broadening of application areas within the industry. Key trends expected in this period encompass significant technological advancements, an increase in strategic collaborations, a rising presence in agricultural applications, an expanding role in industrial processes, and an increasing focus on customization and personalization within the field.

The growing volume of research and laboratory assessments is poised to ignite expansion within the non-therapeutic biomolecules market. Laboratory testing involves the analysis of bodily samples like blood or urine to diagnose and monitor diseases, while research involves generating new knowledge or innovatively applying existing concepts. Non-therapeutic biomolecules, integral to laboratory testing, aid in gauging biomarker molecule presence or concentration, amplifying test sensitivity and accuracy. For instance, the American Association for Clinical Chemistry reports that over 200,000 CLIA-certified labs in the US conduct nearly 13 billion tests yearly, with laboratory services constituting 2.3% of healthcare expenses and two percent of Medicare expenditures, thereby fueling the growth of the non-therapeutic biomolecules market.

The surge in healthcare expenditure is anticipated to drive growth in the non-therapeutic biomolecules market. Increased healthcare spending typically translates to amplified funding for medical research and development. Non-therapeutic biomolecules play a crucial role in diagnostic tools and tests. Heightened healthcare investment often signals a stronger emphasis on disease prevention, early detection, and personalized medicine. This heightened focus on diagnostics stands to contribute significantly to the expansion of the non-therapeutic biomolecules market. As evidenced in the Economic Survey of 2022 by the Ministry of Finance, Government of India, the country's healthcare expenditure surged to 2.1% of GDP in 2021-22 from 1.8% in 2020-21, indicating a driving force behind the market's growth during the forecast period.

Product innovation emerges as a prominent trend in the non-therapeutic biomolecules market. Major industry players concentrate on research and development to introduce innovative products, fortifying their market position. An example is BASF SE collaborating with Caregen in January 2022 to unveil the Peptovitae series, employing liposome-encapsulation technology in dermo-cosmetics. This series addresses diverse skin concerns like aging signs, skin brightness enhancement, dryness relief, and moisturization, showcasing the potential of innovative biomolecule applications.

Companies in the non-therapeutic biomolecules sector prioritize developing advanced cell separation technologies for competitive advantage. Notably, Akadeum Life Sciences launched the Microbubble Leukopak Human T Cell Isolation Kit in September 2022, revolutionizing cell separation. This kit utilizes microbubble technology combined with Buoyancy Activated Cell Sorting (BACSTM) Separation Tubes, enhancing productivity by processing double the leukopaks in one-third of the usual time, thereby optimizing laboratory operations.
In July 2021, Eli Lilly and Company, a US-based multinational pharmaceutical company acquired Protomer Technologies for $1 billion. Through this acquisition, Eli Lilly and Company aims to strengthen its product portfolio in biomolecules and accelerate the development of these next-generation therapeutics. Protomer Technologies is a US-based manufacturing and engineering of peptide molecules, including non-therapeutics molecule.

Major companies operating in the non-therapeutic biomolecules market report are ABB Ltd., Schneider Electric SE, Eaton Corporation PLC, Larsen & Toubro Ltd., Siemens AG, LS Electric Co. Ltd., Entec Electric & Electronic Co. Ltd., EPE Switchgear (M) Sdn. Bhd, Lucy Electric Ltd., Ormazabal Corporación Empresarial S.L., Crompton Greaves Consumer Electricals Limited, Orecco Electric d.o.o, Alfanar Group Ltd., LSIS Co.Ltd., Toshiba Corp., CG Power & Industrial Solutions Ltd., SwitchGear Company NV, NOJA Power Switchgear Pty Ltd., G&W Electric Company, C&S Electric Limited, E+I Engineering Ltd., Hawker Siddeley Switchgear Ltd., Kappa Engineering (Pty) Ltd., KONČAR - Electrical Industry Inc., Laxmi Electronics Pvt. Ltd., MGC Moser-Glaser AG, Mors Smitt B.V, Nissin Electric Co. Ltd., RPS Switchgear Limited, S&S Power Switchgear Limited, Slaters Electricals Ltd., Switchgear Power Systems LLC, Tavrida Electric AG, TE Connectivity Ltd., TGOOD Global Ltd., Trayer Engineering Corporation, VEO Oy, Wahah Electric Supply Company of Saudi Arabia Co., Xiamen Huadian Switchgear Co. Ltd.

Asia-Pacific was the largest region in the non-therapeutic biomolecules market share in 2023. The regions covered in the non-therapeutic biomolecules market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-therapeutic biomolecules market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-therapeutic biomolecule market consists of sales of monosaccharides, disaccharides, polysaccharides, heteropolysaccharides, structural proteins, hormones, respiratory pigments, storage proteins, toxins, deoxyribonucleic acids (DNA), ribonucleic acids (RNA), fatty acids, phospholipids, steroids, eicosanoids, and glycolipids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.